A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating advanced rectal ...
Precision medicine in endometrial cancer emphasizes molecular drivers, challenging traditional histopathologic approaches and ...
The trial evaluates survival outcomes for recurrent head and neck squamous cell carcinoma post-radiation therapy, comparing ...
The FDA has granted approval to a larger vial size of nelarabine injection (SH-111) for use in treatment of adult and ...
Nutritional compromise in cervical cancer patients undergoing chemoradiotherapy predicts poor survival, increased toxicity, ...
In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses ...
Bria-IMT demonstrates a median overall survival of 15.6 months, surpassing historical data for heavily pretreated metastatic ...
Abemaciclib improved progression-free survival at 6 months in meningiomas with NF2 or CDK pathway alterations, achieving a 58 ...
With a median follow-up of 4.2 years, patients receiving blinatumomab achieved a 4-year disease-free survival (DFS) of 83.3% ...
The FDA has granted breakthrough therapy designation (BTD) for bezuclastinib in combination with sunitinib (Sutent) for the ...
New trial results reveal zanidatamab significantly improves survival in HER2-positive advanced gastroesophageal ...
The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results